XuanZhuBio-B (02575) rose more than 18% during morning trading. At the time of writing, the stock was up 11.85% to HK$40.58, with a turnover of HK$18.864 million. The surge follows an announcement on March 24 that the final analysis results of the Phase III BRIGHT-2 clinical study for the company's self-developed novel CDK2/4/6 inhibitor, Bireociclib, have been officially published online in the prestigious international medical journal JAMA Oncology (a Q1 medical journal with an impact factor of 20.1). The BRIGHT-2 study is a randomized, double-blind, placebo-controlled, multicenter Phase III clinical trial conducted in China. It was designed to evaluate the efficacy and safety of Bireociclib combined with fulvestrant in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer whose disease had progressed after prior endocrine therapy. The study was led by Academician Xu Binghe from the Chinese Academy of Medical Sciences Cancer Hospital and conducted across 64 hospitals in China. The company had previously announced interim analysis results from the BRIGHT-2 study in the journal Nature Communications in April 2025. The newly published final analysis results include an additional 11 months of observation beyond the interim analysis, extending the median follow-up time to 19 months, which further demonstrates the maturity and robustness of the survival benefit associated with Bireociclib.
Comments